(Q35027806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Salvatore Lopez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Elena Bonazzoli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Delia Mezzanzanica

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Stefania Bellone

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Emiliano Cocco

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Carlton L Schwab

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jonathan D Black

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Floriana Centritto

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Liancheng Zhu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Natalia Buza

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Pei Hui

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Silvana Canevari

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Peter E Schwartz

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Thomas J Rutherford

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Alessandro D Santin

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

15 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

Clinical & Experimental Metastasis

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

29-38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10585-014-9688-8

22 February 2020

exact match

0 references

cites work

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Targeting the ERBB family in cancer: couples therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Trastuzumab emtansine for HER2-positive advanced breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Carcinosarcoma of the ovary: a review of the literature

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Pathology of mixed Müllerian tumours

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

The role of HER2 in cancer therapy and targeted drug delivery

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Carcinosarcoma of the ovary a review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Unraveling the biologic and clinical complexities of HER2.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Current management of ovarian carcinosarcoma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Clinical features and outcomes of uterine and ovarian carcinosarcoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

ERBB-2 gene overexpression and amplification in uterine sarcomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310789

Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.

8 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-014-9688-8

Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-014-9688-8

Malignant mixed mullerian tumour of the ovary: Prognostic factor and response of adjuvant platinum‐based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-014-9688-8

HER2 aberrations in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-014-9688-8

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-014-9688-8

EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-014-9688-8

COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-014-9688-8

Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-014-9688-8

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-014-9688-8

Different expression patterns of KIT, EGFR, and HER‐2 (c‐erbB‐2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25398397

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25398397

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25398397

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10585-014-9688-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25398397%20AND%20SRC:MED&resulttype=core&format=json